IDEXX Laboratories, Inc.'s Stock Analysis

IDEXX Laboratories Shareholder Meeting Approves Key Governance Changes

At the 2026 annual meeting held on May 12, shareholders of IDEXX Laboratories approved significant amendments to the company's Certificate of Incorporation. These amendments include the declassification of the Board of Directors over a three-year period, allowing for annual elections starting in 2029, and granting shareholders owning at least 25% of the shares the right to request special meetings, subject to certain conditions. A Certificate of Amendment reflecting these changes was filed and became effective on May 13, 2026.

Additionally, the company amended its By-Laws to align with the new governance structure, including provisions for the special meeting requests. Shareholders also voted on the election of three Class II directors, the appointment of PricewaterhouseCoopers LLP as the independent accounting firm, and the advisory approval of executive compensation. The results of these votes were documented in the Proxy Statement filed with the SEC.

May 15, 2026 16:00:10

IDEXX Laboratories Reports Q1 2026 Financial Results and Outlook

IDEXX Laboratories, Inc. reported first-quarter revenues of $1,141 million for 2026, marking a 14% increase compared to the previous year. Growth was primarily driven by the Companion Animal Group (CAG), which saw a 15% increase in revenue. Earnings per diluted share were reported at $3.47, reflecting a 17% increase. The company noted strong performance in diagnostics and capital instruments, with recurring revenue growth of 14% in the CAG Diagnostics segment. The gross profit increased by 16%, and the operating margin stood at 31.8%.

For the full year, IDEXX updated its revenue guidance to a range of $4,675 million to $4,760 million, indicating a growth of 8.6% to 10.6%. The company also raised its outlook for organic revenue growth to 7.7% to 9.7% and increased its EPS forecast to between $14.45 and $14.90. The adjustments reflect strong first-quarter performance and expectations of improving clinical visit trends. IDEXX continues to invest in its innovation strategy and expects to see further growth in its diagnostics and software services.

May 05, 2026 06:31:53

IDEXX Laboratories Announces Departure of Executive Vice President

IDEXX Laboratories, Inc. has announced that Dr. Nimrata Hunt will cease her role as Executive Vice President, Global Strategy and Commercial, effective April 13, 2026. Following her departure, she will provide advisory services until July 13, 2026. A separation agreement has been established, which includes salary continuation, bonus payments, and other benefits totaling approximately $2.27 million, alongside provisions regarding stock options and confidentiality agreements.

Dr. Hunt's position is being eliminated, and her separation is classified as a termination without cause, impacting her separation benefits. The agreement includes a release of claims in favor of IDEXX and stipulates that any unvested stock awards will be forfeited. IDEXX will continue to compensate her for advisory services on a per diem basis until her final employment date.

Mar 26, 2026 08:30:22

IDEXX Laboratories Board Member Announces Retirement Plans

Ms. M. Anne Szostak has informed IDEXX Laboratories of her intention to retire from the Board of Directors, effective after the 2026 Annual Meeting scheduled for May 12, 2026. Her decision is not due to any disagreements with the Company or the Board regarding operations or policies.

Following Ms. Szostak's retirement, the Board will reduce the size of Class III but will maintain the overall size of the Board due to the appointment of Michael G. Erickson, PhD, as a Class II member, effective after the same Annual Meeting.

Feb 13, 2026 17:00:07

IDEXX Laboratories Reports Strong Q4 and Full Year 2025 Results

IDEXX Laboratories, Inc. reported revenues of $1,091 million for the fourth quarter of 2025, reflecting a 14% increase compared to the same period in the previous year. The growth was primarily driven by a 15% rise in Companion Animal Group (CAG) revenues and a 12% increase in Water revenues. Earnings per diluted share (EPS) for the quarter were $3.08, up 18% from the prior year, with operating margins expanding by 150 basis points. For the full year, revenues reached $4,304 million, a 10% increase, with EPS of $13.08, marking a 23% rise year-over-year.

The company anticipates revenue growth for 2026 in the range of $4,632 million to $4,720 million, supported by expected CAG Diagnostics recurring revenue growth of 8.6% to 10.6%. The projected EPS for 2026 is between $14.29 and $14.80. IDEXX noted significant achievements in diagnostics innovation, including the launch of IDEXX Cancer Dx for canine lymphoma, which contributed to their overall growth strategy. The company continues to focus on expanding its global presence and enhancing its product offerings.

Feb 02, 2026 06:39:21

IDEXX Laboratories Announces CEO Transition and Compensation Details

IDEXX Laboratories has announced a leadership transition, with Jonathan (Jay) Mazelsky stepping down as President and CEO on May 12, 2026, to become Executive Chair of the Board. Michael (Mike) Erickson, PhD, currently Executive Vice President, will succeed him as President and CEO and join the Board. The transition is set to ensure continuity, with Mazelsky assisting Erickson until his retirement in May 2027. Erickson's compensation package includes a base salary of $1 million, a target annual bonus of 120% of his salary, and long-term equity awards valued at a minimum of $7.8 million for the 2026 fiscal year.

Additionally, both Mazelsky and Erickson have entered into agreements detailing their compensation and benefits during this transition period. Mazelsky will receive an annual salary of $1.15 million as Executive Chair and is expected to receive equity awards valued at $8.275 million for the 2026 fiscal year. The agreements also outline provisions for termination without cause, ensuring both executives are entitled to certain benefits if their employment is ended under specified conditions. These leadership changes and compensation arrangements may influence investor sentiment regarding the company's future performance.

Jan 13, 2026 08:33:54

IDEXX Laboratories Amends Credit Agreement for $1 Billion Facility

IDEXX Laboratories, Inc. has entered into an amendment to its existing credit agreement, enhancing its financial flexibility through a five-year unsecured revolving credit facility of $1 billion and a term loan facility of $250 million. This amendment allows IDEXX Holdings II GmbH to assume certain borrowing rights and obligations, while also introducing provisions for incremental borrowing capabilities of up to $250 million. Borrowings under this agreement can be utilized for general corporate purposes and are subject to interest rates that vary based on the company's consolidated leverage ratio.

The amended credit agreement includes customary covenants and stipulations, such as restrictions on liens and indebtedness, and requires any new material U.S. subsidiaries to guarantee the obligations under the agreement. The company must adhere to various financial covenants, including maintaining a specified consolidated leverage ratio. Events of default could lead to the acceleration of obligations under the agreement, which encompasses typical defaults related to payments, covenants, and changes in control.

Nov 13, 2025 16:07:10

IDEXX Laboratories Reports Third Quarter 2025 Financial Results

On November 3, 2025, IDEXX Laboratories reported third quarter revenues of $1,105 million, reflecting a 13% increase year-over-year. This growth was driven by a 14% increase in the Companion Animal Group (CAG) and a 17% rise in Livestock, Poultry, and Dairy (LPD) revenues. The earnings per diluted share (EPS) for the quarter were $3.40, marking a 21% increase. The company noted significant growth in diagnostic recurring revenue and capital instrument sales, particularly in the U.S. and international markets.

IDEXX Laboratories updated its full-year revenue guidance to a range of $4,270 million to $4,300 million, indicating a reported growth of 9.6% to 10.3%. The company also raised its EPS outlook to between $12.81 and $13.01, reflecting a growth of 20% to 22% year-over-year. Operating margins for the third quarter were reported at 32.1%, up 100 basis points from the previous year, supported by productivity initiatives and net price realization. The company continues to invest in innovation and commercial resources to drive future growth.

Nov 03, 2025 06:34:17

IDEXX Laboratories Elects New Independent Director Karen Peacock

IDEXX Laboratories, Inc. has appointed Karen Peacock as an independent Class I Director, effective October 6, 2025. This decision increased the Board's size from ten to eleven members and the Class I Directors from three to four. Ms. Peacock is expected to stand for election by stockholders at the 2027 annual meeting. She will receive compensation comparable to other non-employee Directors and will be eligible for certain deferred compensation arrangements.

Ms. Peacock brings extensive experience in B2B, SaaS software, and AI, having previously served as the CEO of Intercom, Inc., and in various senior roles at Intuit Inc. She currently serves on the board of Dropbox as the lead independent director. Her appointment is anticipated to enhance the Board's effectiveness, contributing to IDEXX's focus on advancing pet healthcare through innovative diagnostics and software solutions.

Oct 07, 2025 07:06:51

IDEXX Laboratories Reports Q2 2025 Financial Results and Outlook

IDEXX Laboratories, Inc. announced its financial results for the second quarter of 2025, reporting revenues of $1,109 million, which reflects an 11% increase compared to the previous year. The growth was driven primarily by the Companion Animal Group (CAG), which saw an 11% increase in revenue, and Water revenue, which grew by 9%. Earnings per diluted share (EPS) for the quarter were $3.63, marking a 49% increase, aided by various tax benefits and currency changes. The company's gross profit rose 12%, with an operating margin of 33.6%, significantly higher than the prior year due to improved operational efficiencies and pricing strategies.

In light of the strong performance, IDEXX updated its full-year revenue growth guidance to a range of $4,205 million to $4,280 million, representing a 7.7% to 9.7% increase. The company also increased its EPS outlook to between $12.40 and $12.76, reflecting a positive adjustment due to operational performance and favorable foreign exchange estimates. IDEXX continues to focus on expanding its diagnostic solutions and maintaining customer loyalty, which it anticipates will support sustained growth moving forward.

Aug 04, 2025 06:30:59